These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 34435030

  • 1. Long-term effect of α1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database.
    Schouten IGM, Kasteleyn MJ, Tsonaka R, Bals R, Turner AC, Ferrarotti I, Corsico AG, Lara B, Miravitlles M, Stockley RA, Stolk J.
    ERJ Open Res; 2021 Jul; 7(3):. PubMed ID: 34435030
    [Abstract] [Full Text] [Related]

  • 2. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry.
    Rahaghi FF, Monk R, Ramakrishnan V, Beiko T, Strange C.
    Int J Chron Obstruct Pulmon Dis; 2020 Jul; 15():3193-3199. PubMed ID: 33299307
    [Abstract] [Full Text] [Related]

  • 3. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).
    Esquinas C, Serreri S, Barrecheguren M, Rodriguez E, Nuñez A, Casas-Maldonado F, Blanco I, Pirina P, Lara B, Miravitlles M.
    Int J Chron Obstruct Pulmon Dis; 2018 Jul; 13():1001-1007. PubMed ID: 29615836
    [Abstract] [Full Text] [Related]

  • 4. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis.
    Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ.
    COPD; 2009 Jun; 6(3):177-84. PubMed ID: 19811373
    [Abstract] [Full Text] [Related]

  • 5. Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.
    Fraughen DD, Ghosh AJ, Hobbs BD, Funk GC, Meischl T, Clarenbach CF, Sievi NA, Schmid-Scherzer K, McElvaney OJ, Murphy MP, Roche AD, Clarke L, Strand M, Vafai-Tabrizi F, Kelly G, Gunaratnam C, Carroll TP, McElvaney NG.
    Am J Respir Crit Care Med; 2023 Nov 01; 208(9):964-974. PubMed ID: 37624745
    [Abstract] [Full Text] [Related]

  • 6. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
    Am J Respir Crit Care Med; 1998 Jul 01; 158(1):49-59. PubMed ID: 9655706
    [Abstract] [Full Text] [Related]

  • 7. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society.
    Abboud RT, Ford GT, Chapman KR, Stnadards Committee of the Canadian Thoracic Society.
    Can Respir J; 2001 Jul 01; 8(2):81-8. PubMed ID: 11320399
    [Abstract] [Full Text] [Related]

  • 8. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
    Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N.
    Eur Respir J; 1997 Oct 01; 10(10):2260-3. PubMed ID: 9387950
    [Abstract] [Full Text] [Related]

  • 9. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency.
    Fähndrich S, Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, Bals R.
    Respir Med; 2017 Aug 01; 129():8-15. PubMed ID: 28732839
    [Abstract] [Full Text] [Related]

  • 10. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
    Wencker M, Banik N, Buhl R, Seidel R, Konietzko N.
    Eur Respir J; 1998 Feb 01; 11(2):428-33. PubMed ID: 9551749
    [Abstract] [Full Text] [Related]

  • 11. Alpha-1 Antitrypsin Augmentation and the Liver Phenotype of Adults With Alpha-1 Antitrypsin Deficiency (Genotype Pi∗ZZ).
    Fromme M, Hamesch K, Schneider CV, Mandorfer M, Pons M, Thorhauge KH, Pereira V, Sperl J, Frankova S, Reichert MC, Benini F, Burbaum B, Kleinjans M, Amzou S, Rademacher L, Bewersdorf L, Verbeek J, Nevens F, Genesca J, Miravitlles M, Nuñez A, Schaefer B, Zoller H, Janciauskiene S, Waern J, Oliveira A, Maia L, Simões C, Mahadeva R, Fraughen DD, Trauner M, Krag A, Lammert F, Bals R, Gaisa NT, Aigner E, Griffiths WJ, Denk H, Teumer A, McElvaney NG, Turner AM, Trautwein C, Strnad P.
    Clin Gastroenterol Hepatol; 2024 Feb 01; 22(2):283-294.e5. PubMed ID: 37716616
    [Abstract] [Full Text] [Related]

  • 12. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.
    Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML.
    Int J Chron Obstruct Pulmon Dis; 2009 Feb 01; 4():443-52. PubMed ID: 20054436
    [Abstract] [Full Text] [Related]

  • 13. [Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].
    Wencker M, Banik N, Buhl R, Seidel R, Konietzko N.
    Pneumologie; 1998 Oct 01; 52(10):545-52. PubMed ID: 9847632
    [Abstract] [Full Text] [Related]

  • 14. The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency.
    Banga A, Gildea T, Rajeswaran J, Rokadia H, Blackstone EH, Stoller JK.
    Am J Respir Crit Care Med; 2014 Aug 01; 190(3):274-81. PubMed ID: 25003824
    [Abstract] [Full Text] [Related]

  • 15. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
    Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG, RAPID Trial Study Group.
    Lancet; 2015 Jul 25; 386(9991):360-8. PubMed ID: 26026936
    [Abstract] [Full Text] [Related]

  • 16. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry.
    Miravitlles M, Turner AM, Torres-Duran M, Tanash H, Rodríguez-García C, López-Campos JL, Chlumsky J, Guimaraes C, Rodríguez-Hermosa JL, Corsico A, Martinez-González C, Hernández-Pérez JM, Bustamante A, Parr DG, Casas-Maldonado F, Hecimovic A, Janssens W, Lara B, Barrecheguren M, González C, Stolk J, Esquinas C, Clarenbach CF.
    Respir Res; 2022 Dec 16; 23(1):352. PubMed ID: 36527073
    [Abstract] [Full Text] [Related]

  • 17. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease.
    Stoller JK, Aboussouan LS, Kanner RE, Wilson LA, Diaz P, Wise R, LOTT Research Group.
    Ann Am Thorac Soc; 2015 Dec 16; 12(12):1796-804. PubMed ID: 26653189
    [Abstract] [Full Text] [Related]

  • 18. Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group.
    Greulich T, Albert A, Cassel W, Boeselt T, Peychev E, Klemmer A, Ferreira F, Clarenbach C, Torres-Duran ML, Turner AM, Miravitlles M.
    Int J Chron Obstruct Pulmon Dis; 2022 Dec 16; 17():53-64. PubMed ID: 35023913
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish registry.
    Tirado-Conde G, Lara B, Casas F, Blanco I, Bustamante A, Cadenas S, Martínez MT, Lázaro L, Torres M, Hernández Pérez JM, Vidal R, Miravitlles M.
    Arch Bronconeumol; 2011 Oct 16; 47(10):495-503. PubMed ID: 21798656
    [Abstract] [Full Text] [Related]

  • 20. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
    Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR.
    Int J Chron Obstruct Pulmon Dis; 2012 Oct 16; 7():687-96. PubMed ID: 23055718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.